Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study suggests that individuals who have previously had COVID-19 are highly unlikely to contract the illness again, for at least six months following their first infection.

3d illustration of coronavirus

The study, done as part of a major collaboration between the University of Oxford and Oxford University Hospitals (OUH) NHS Foundation Trust, was published today as a pre-print.

Despite an estimated 51 million people infected with the virus worldwide, with high levels of transmission ongoing, reports of patients becoming re-infected after already having had COVID-19 are rare. However, up until now there have not been any large-scale studies of how much protection from re-infection people get after COVID-19.

The study, part of a major ongoing staff testing programme supported by the NIHR Oxford Biomedical Research Centre and Public Health England, covered a 30-week period (April – November 2020) with 12,180 health care workers employed at OUH. The health care workers were tested for antibodies to the virus that causes COVID-19 as a way of detecting who had been infected before. The hospital tested staff regularly for COVID-19, both when they became unwell with symptoms and also as part of regular testing of well staff. The researchers then followed whether staff who had been infected before had the same number of new COVID-19 infections as those who had not been infected before.

The full story is available on the University of Oxford website

Similar stories

Oxford vaccine creator Professor Sarah Gilbert awarded RSA Albert Medal

Awards and Appointments Coronavirus COVID-19 General Innovation Research

Professor Sarah Gilbert has been awarded the Royal Society for Arts, Manufactures and Commerce’ (RSA) Albert Medal for her work on the Oxford vaccine.

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

Regular meat consumption linked with a wide range of common diseases

Research

Regular meat consumption is associated with a range of diseases that researchers had not previously considered, according to a large, population-level study conducted by a team at the University of Oxford.

New data show vaccines reduce severe COVID-19 in older adults

Coronavirus COVID-19 Research

New data show both Oxford / AstraZeneca vaccine and the Pfizer-BioNTech vaccines significantly reduce severe COVID-19 in older adults.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.